EU approves Gilead's Trodelvy for first-line metastatic TNBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall Street indexes dip with technology earnings, rising oil in focus
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- Oil settles up more than 3% to six-week high as Mideast conflict threatens oil transit routes
- Can Alphabet earnings reignite investor enthusiasm for the Magnificent Seven?
European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
June 23, 2026 7:45 AM EDTTrodelvy is the First Antibody-Drug Conjugate (ADC) and First New Treatment Option in 20 Years in Europe for Certain Patients with First-Line Metastatic Triple-Negative Breast Cancer
Authorization Based on ASCENT-03 Study in Which Trodelvy Demonstrated Highly Statistically Significant and Clinically Meaningful Progression-Free Survival (PFS) Versus Chemotherapy in PD-(L)1 Inhibitor Ineligible Patients
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) as monotherapy for the treatment of adult patients... More
